Enlivex Therapeutics Enters Securities Purchase Agreement
Ticker: ENLV · Form: 6-K · Filed: May 29, 2024 · CIK: 1596812
Sentiment: neutral
Topics: securities-agreement, foreign-private-issuer, capital-raise
TL;DR
Enlivex inked a deal with an investor on May 27th, 2024.
AI Summary
On May 27, 2024, Enlivex Therapeutics Ltd. entered into a securities purchase agreement with a single investor. The company, incorporated in Israel, is a pharmaceutical preparations company previously known as Bioblast Pharma Ltd. This filing is a report of a foreign private issuer.
Why It Matters
This agreement signifies a capital raise or strategic investment for Enlivex Therapeutics, potentially impacting its research and development funding and future operations.
Risk Assessment
Risk Level: medium — Entering into a securities purchase agreement can indicate a need for capital, which may signal financial challenges or significant upcoming expenses.
Key Players & Entities
- Enlivex Therapeutics Ltd. (company) — Registrant
- May 27, 2024 (date) — Date of Securities Purchase Agreement
- Securities Purchase Agreement (document) — Agreement entered into by Enlivex
- Bioblast Pharma Ltd. (company) — Former name of Enlivex Therapeutics Ltd.
FAQ
What is the primary purpose of the securities purchase agreement?
The filing states that Enlivex Therapeutics Ltd. entered into a securities purchase agreement on May 27, 2024, but does not specify the primary purpose beyond the agreement itself.
Who is the single investor involved in the securities purchase agreement?
The filing mentions a 'single investor' but does not disclose their identity.
What is Enlivex Therapeutics Ltd.'s principal executive office address?
Enlivex Therapeutics Ltd.'s principal executive offices are located at 14 Einstein Street, Nes Ziona, Israel 7403618.
When did Enlivex Therapeutics Ltd. change its name from Bioblast Pharma Ltd.?
The company formerly known as Bioblast Pharma Ltd. changed its name to Enlivex Therapeutics Ltd. on September 19, 2016.
Is Enlivex Therapeutics Ltd. required to file annual reports on Form 20-F or 40-F?
Enlivex Therapeutics Ltd. is required to file annual reports under cover of Form 20-F.
Filing Stats: 1,265 words · 5 min read · ~4 pages · Grade level 11.4 · Accepted 2024-05-29 16:20:04
Key Financial Figures
- $1.40 — ;), at a combined purchase price of (a) $1.40 per Ordinary Share and the associated I
- $1.399 — to purchase one Ordinary Share, and (b) $1.399 per Pre-Funded Warrant and the associat
- $0.001 — Funded Warrant has an exercise price of $0.001 per Ordinary Share, is immediately exer
- $1.75 — that they are exercisable at a price of $1.75 per Ordinary Share, and the Series B Wa
- $25,000 — gross proceeds raised in the Offering, $25,000 for non-accountable expenses, up to $50
- $50,000 — 000 for non-accountable expenses, up to $50,000 for reasonable and documented fees and
- $15,950 — l and other out-of-pocket expenses, and $15,950 for clearing fees. The closing of the
- $4.5 million — ds from the Offering were approximately $4.5 million after deducting Wainwright’s fees
Filing Documents
- ea0206989-6k_enlivex.htm (6-K) — 22KB
- ea020698901ex1-1_enlivex.htm (EX-1.1) — 207KB
- ea020698901ex4-1_enlivex.htm (EX-4.1) — 90KB
- ea020698901ex4-2_enlivex.htm (EX-4.2) — 89KB
- ea020698901ex4-3_enlivex.htm (EX-4.3) — 85KB
- ea020698901ex4-4_enlivex.htm (EX-4.4) — 107KB
- ea020698901ex4-5_enlivex.htm (EX-4.5) — 107KB
- ea020698901ex5-1_enlivex.htm (EX-5.1) — 13KB
- ea020698901ex5-2_enlivex.htm (EX-5.2) — 18KB
- ea020698901ex99-1_enlivex.htm (EX-99.1) — 11KB
- ex5-1_001.jpg (GRAPHIC) — 20KB
- ex5-2_001.jpg (GRAPHIC) — 8KB
- ex99-1_001.jpg (GRAPHIC) — 8KB
- 0001213900-24-047469.txt ( ) — 801KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Enlivex Therapeutics Ltd. (Registrant) By: /s/ Oren Hershkovitz Name: Title: Oren Hershkovitz Chief Executive Officer Date: May 29, 2024 3